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Metastasis and resistance to therapy signiﬁcantly contribute to cancer-related deaths. Growing body of
evidence suggest that altered expression of microRNAs (miRNAs) is one of the root cause of adverse
clinical outcome. miRNAs such as let-7 are the new ﬁne tuners of signaling cascade and cellular processes
which regulates the genes in post-transcriptional manner. In this review, we described the regulation of
let-7 expression and the involvement of molecular factors in this process. We discussed the mechanism
by which let-7 alter the expression of genes involved in the process of tumorigenesis. Further, we listed
the pathways targeted by let-7 to reduce the burden of the tumor. In addition, we described the role of
let-7 in breast cancer metastasis and stemness properties. This article will provide the in-depth insight
into the biology of let-7 miRNA and its role in the breast cancer progression.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Breast cancer (BC) is most frequently diagnosed cancer and re-
mains one of leading cause of cancer-related death in women
worldwide [1,2]. Altered signaling pathways [3e7], mutation in
genes [8], activation of oncogenic pathways [9e11], DNA damage
[12,13] and non-targeted effects of chemotherapeutic agents
[14e17] signiﬁcantly contributes in cancer progression. Therapeutic
strategies including chemotherapy [18], application of toxins ob-
tained from pathogen [19e24] have shown limited clinical efﬁcacy
against cancer. During past one and half decade, enormous growth
in the ﬁeld of microRNAs (miRNAs) biology have been witnessed
and it has been suggested that targeting these small molecules
holds potential therapeutic efﬁcacy for cancer [25e27]. miRNAs are
evolutionary conserved, single-stranded and contains approxi-
mately 22 nucleotides RNA molecules that alter the expression of
gene at the post-transcriptional level [28]. In nucleus miRNAs are
transcribed by RNA polymerase II as pri-miRNAs and subsequently
cleaved by ribonuclease III, Drosha, to form a ~70 nucleotide long
pre-miRNA. Thereafter, the pre-miRNA are transported to theancer; IL-6, interleukin-6; 30
polymorphisms; NF, nuclear
al transducer and activator of
maiah).
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18e25 nucleotide long miRNA duplex. After unwinding, one of the
strands incorporated into the RNA-induced silencing complex, that
subsequently interacts with complementary sequences in the 30
untranslated regions (30 UTRs) of the target mRNA transcripts. A
single miRNA is capable of regulating multiple mRNAs of various
functions. Further, dysregulation of miRNAs abrogate the normal
functioning of the cellular system that promotes several patho-
logical conditions such as cancer [29,30]. Abnormal expression of
miRNAs such as let-7 has been reported in several malignancies
including BC. In year 2000 Reinhart et al. demonstrated that let-7
miRNA alter the phenotype of nematode and regulates the devel-
opment of Caenorhabditis elegans [30]. In human, 10 members of
the let-7 family have been identiﬁed, including let-7a, let-7b, let-7c,
let-7d, let-7e, let-7f, let-7g, let-7i, miR-98 and miR-202. In normal
physiological conditions let-7 is primarily involved in gene regu-
lation, cell adhesion and muscle formation. Accumulating evidence
suggests that let-7 is downregulated in numerous types of cancer,
including gastric tumors [31], colon cancer [32], lung cancer [33],
Burkitt's lymphoma [34] and BC [35]. The let-7 family of miRNA is
associatedwith apoptosis, proliferation and invasion of cancer cells.
Further, let-7 regulates several signaling pathways that are crucial
for the biological characteristics of tumor cells. In this review article
we have explored the possible factors associated with let-7
expression and its mechanisms of action. Further, we described the
target of let-7 that are important for BC cell growth, aggressiveness
and explored the beneﬁts of targeting let-7 to control the BCAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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2. Regulation of miRNA let-7 expression
Role of let-7 in cell proliferation and differentiation have been
demonstrated in animal and human cell lines [36e38]. Interest-
ingly let-7 has been implicated in inhibiting the growth of cancer
cells [39,40]. microRNA let-7 expression is important to explore as it
involved in the tumor suppression. let-7 expression is controlled at
various stages biogenesis which involves numerous factors and
signaling molecule (Fig. 1). In this section we described the factors
that are known to regulate the expression of let-7 in BC.
2.1. Regulation of miRNA let-7 by Lin28
Lin28 encodes a RNA-binding protein that is known to bind let-7
pre-microRNA. The activity of let-7was demonstrated to be affected
by mutations in Lin28 [30]. Lin28 and its subtype Lin28B have been
suggested to bind to hairpin and the stem of pri-let-7 and inhibit
the binding of Dicer, thus inhibiting its processing and biogenesis
[41,42]. In addition, binding of Lin28 to the terminal loop region of
let-7g has also been demonstrated [43]. Importantly, the zinc-ﬁnger
and cold-shock domains in Lin28were determined to be crucial for
pre-let-7 binding. Further, upregulation of Lin28 were shown to
inhibit the let-7g processing. Ectopic expression of Lin28 abrogates
the processing of pri-let-7a suggesting, that Lin28 is important to
block the microprocessor-mediated cleavage of pri-let-7 miRNAs
[44]. Further, the transfection of Lin28 reduces the endogenous
levels of let-7 [44]. Other than Drosha/Dicer inhibition, Lin28/
Lin28B is shown to block the let-7 processing by terminal uridyla-
tion of pre-let-7 that leads to the irreversibly re-routing pre-let-7 to
a degradation pathway [45]. Several enzymes including Zcchc11, a
terminal uridylyl transferase 4 (TUT4) have been suggested to be
involved in the progress of terminal uridylation. The TUT4 has been
found to promote the pre-let-7 uridylation and blockade of let-7
processing in mouse embryonic stem cells [46]. Lin28 recruit TUT4
to pre-let-7 by recognizing tetranucleotide sequence motif (GGAG)
in the loop. Later the TUT4 adds an oligouridine tail to pre-let-7 that
subsequently blocks Dicer processing [47]. Further, the interaction
of PUP-2 with Lin28 controls the stability of Lin28-blockaded let-7
pre-miRNAwhich suppress the action of Dicer and contribute to theFig. 1. Signaling pathways involved in miRNA let-7 expression.
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2.2. Regulation of miRNA let-7 by nuclear factor 90 and nuclear
factor 45
Nuclear factor (NF) 90 and NF45 are the member of Drosha
family, which is crucial for the production of pre-miRNA from pri-
miRNA. Altered expression of NF90 and NF45 is found to be asso-
ciated with the level of pri-miRNA. The NF90-NF45 complex is
shown to bind with the majority of pri-miRNAs, including pri-let-
7a-1 and has higher binding afﬁnity than the DGCR8-Drosha
complex, which also binds to pri-miRNAs. Due to elevated bind-
ing afﬁnity, NF90-NF45 complex attenuate the processing of pri-
miRNA by the DGCR8-Drosha complex. The NF90-NF45 have been
shown to have higher binding afﬁnity for pri-let-7a-1 than the other
pri-miRNAs [49].
2.3. Regulation of miRNA let-7 by other factors
DNAmethylation is considered to be one of the reason that alter
miRNA let-7 expression [50e52]. The human let-7 gene is located
on chromosome 22q13.31, which is known to be methylated by the
DNA methyltransferases such as DNMT3B and DNMT1. The miRNA
let-7a-3 is found to bemethylated in lung samples. Interestingly the
hypomethylation of let-7a-3 promotes the expression ofmiRNA and
reduce the growth of lung adenocarcinomas cells [52]. Moreover,
hypermethylation downregulated the let-7a-3 in epithelial ovarian
cancer and associated with unfavorable prognosis [53]. Several
factors act at the time of let-7 biogenesis and control the expression
of let-7 via regulatory loops. These loops can be either Lin28-
dependent or Lin28-independent. The Lin28-dependent regulatory
feedback loop involves the NFkB-Lin28-let-7-interleukin (IL)-6-
NFkB, and Lin28-let-7-Lin28 loops. The NFkB is shown to activate
Lin28 transcription and reduces let-7 levels. Further, let-7 can
inhibit IL-6 expression that can activate NFkB, and completing a
positive feedback loop [54]. c-Myc, an oncogene is one of the target
of let-7. The expression of c-Myc regulated by IMP1 which is
believed to be negatively and directly regulated by let-7 [55,56].
Further, c-Myc was demonstrated to transactivate Lin28B, which
inhibit let-7 expression. In addition, activation of Lin28B was found
to associate with Myc-mediated let-7 expression [57,58]. Moreover,
let-7 can also affect Lin28 expression as the binding of let-7 to the 30
UTR of Lin28 transcripts represses Lin28 expression [58]. Lin28 is
believed to be a classical direct inhibitor of let-7, which create a
double-negative regulatory loop for let-7. Alteration in regulatory
circuits affects the expression of let-7 that can promote normal and
abnormal responses. A single nucleotide polymorphisms (SNPs) in
tumor suppressor miRNA is believed to be responsible for several
malignancies [59,60]. A SNP of the Lin28 gene, rs3811463 is shown
to be involved in downregulation of let-7 via the let-7-Lin28 double
negative feedback loop. rs3811463 was therefore believed to
involved in breast cancer [61].
2.4. Mechanism of miRNA let-7 mediated response
The best explained mechanism of let-7 miRNA action is binding
to the 30 UTR of target mRNAs to alter their expression. Further, let-7
induces its effect when it was targeted to the 30 or 50 UTRs of
mRNAs, suggesting that let-7 can act via binding to sites other than
the 30 UTR [62]. In addition, let-7 is capable to bind directly to
coding regions to target mRNAs to alter its expression [63]. It has
been suggested that let-7a can inhibit the translation of target
mRNAs by binding and inhibiting the translating polyribosomes
[64]. Deadenylation that is removal of adenylate group fromprotein
is another process that can be exploited by let-7 to inhibit or decayfamily microRNA in breast cancer, Non-coding RNA Research (2016),
C.K. Thammaiah, S. Jayaram / Non-coding RNA Research xxx (2016) 1e6 3the translation of mRNA. However, deadenylation alone seems
insufﬁcient to participate in mRNA repression [65].2.5. Signaling pathways targeted by miRNA let-7
Let-7 is one of the miRNA that targets multiple signaling path-
ways including Janus protein tyrosine kinase (JAK), signal trans-
ducer and activator of transcription 3 (STAT3) and c-Myc. These
pathways are crucial for tumor cell growth and aggressiveness. By
suppressing these oncogenic pathways let-7 act as a tumor
suppressor.2.6. Regulation of JAK-STAT3 pathway by miRNA let-7
The JAK is a member of the intracellular, non-receptor tyrosine
kinases that mediates signals via JAK-STAT3 signaling pathway.
Activated JAK promotes STATs activation, which transmits the in-
formation from extracellular chemical to the nucleus and induces
the expression of genes involved in differentiation, proliferation,
apoptosis, oncogenesis and immunity [66]. The JAK-STAT3 pathway
is believed to be activated in several types of malignancies [67,68].
Interestingly, STAT3 was found to be a target of let-7a, which me-
diates cell proliferation in HepG2 cells [69]. It is speculated that let-
7 may regulate the activity of cancer cells by targeting JAK-STAT3
signaling pathway.2.7. Regulation of Myc oncogene pathway by miRNA let-7
Myc (c-Myc) is a transcription factor that plays an important
role in cell cycle progression and apoptosis. This gene is usually
activated in tumors [70]. Activation of Myc promotes cell growth,
and survival by enhancing the synthesis of its target proteins,
which are associated with cell cycle and apoptosis [71]. In addition
the mutation in Myc gene have been reported in many cancers
which causes this gene to be persistently expressed that leads to
the altered expression of several genes in which are involved in
growth and aggressiveness of the cancer. Altered expression of Myc
has been found in the cancers of colon [72], cervix [73] and breast
[74]. Several reports have been suggested that let-7a down-
regulated Myc mRNA and protein [34,75]. Further, it has been
suggested that miRNA let-7 regulates Myc expression by binding to
its 30 UTR. However, let-7 has been found to regulate the cell cycle
by altering the expression of several downstream proteins such as
cyclin D1 and cyclin-dependent kinase (CDK) 6 that are the part of
Myc oncogene signaling pathway [76,77].Table 1
miRNA let-7 family target genes in various cancers.
S. No. Type of cancer Target gene Gene
1 Thyroid cancer SLC5A5 Sodiu
2 Oral Squamous cell Carcinoma OCT4 octam
3 Ovarian Cancer KRAS Kirste
4 Pancreatic Cancer STAT3 Signa
5 Neuroblastoma MYCN V-My
6 Lung Cancer ITGB3 Integ
7 Liver Cancer HMGA2 High-
8 Prostate Cancer IL-6 Interl
9 Endometrial Cancer Aurora-B Auror
10 Colorectal Cancer KRAS Kirste
11 Gastric Cancer CMYC V-My
12 Multiple Myeloma MYC V-My
13 Burkitts Lymphoma MYC V-My
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BC is one of the leading causes of cancer related death in
women. The poor outcome of BC is attributed to the heterogenous
nature andmetastasis. Another mechanism that helps tumor cell to
grow unchecked is the development of cancer stem cell (CSC)
phenotype. The let-7 microRNAs that regulate the expression of
multiple genes related to the metastasis and stem cell phenotype
and attracted scientiﬁc community to develop targeted therapies
against BC. In this sectionwe brieﬂy discussed the role of let-7 in BC
metastasis and stemness.
2.9. Role of miRNA let-7 in breast cancer metastasis
Metastasis is a process in which cancer cell break away from the
original site and travels the blood or lymphatic system to the other
parts of body and form new tumors. Chemotaxis is believed to be a
fundamental cause of metastasis in which external signals orient
and attract tumor cells. Overexpression of certain receptors facili-
tates BC cells to get attracted and move to other site. CXCR7 is one
of the receptor that is found to be overexpressed in BC and
participate in metastasis [78]. CCR7 is activated by binding che-
mokines CCL21 and CCL19 [79,80]. T cells utilize CCL21 to enter
lymphoid tissues from circulation. As for as CCL19 is concerned, it is
expressed by mature dendritic cells which activates T cells [81].
However, tumor cells exploit the conditions by expressing CCR7
that helps them to localize in lymph node after receiving the
chemotactic signals from CCL19 or CCL21. miRNAs have been sug-
gested to suppress the expression of numerous cancer-related
genes that subsequently reduces tumorigenesis and metastasis in
BC and several other cancers [82e84]. A study examined the roles
of CCR7 andmiRNA in breast cancer metastasis suggested that let-7
family binds participate in the process of metastasis [85]. Let-7a
was found to inﬂuence the CCR7 down expression by targeting
30UTR of CCR7, thereby downregulating BC cell invasion and
migration. Similar results were conﬁrmed in study performed using
zebraﬁsh embryo models. Let-7a, a member of family let-7 act as a
tumor suppressor by regulating the expression of RAS and HMGA2
oncogenes [86e88]. Further, decreased levels of let-7awas found to
associate with elevated RAS expression in lung squamous carci-
noma [86].
2.10. Role of miRNA let-7 in breast cancer stemness
CSCs, a sub-population of tumor cells is believed to be largely
responsible for the therapy resistance and unfavorable clinical
outcome. miRNAs have been suggested to contribute in tumor
initiation by regulating the properties of CSC, including de-title References
m/iodide cotransporter or solute carrier family 5, member 5 [97]
er-binding transcription factor 4 [98]
n rat sarcoma viral oncogene homolog [99]
l transducer and activator of transcription 3 [100]
c Avian Myelocytomatosis Viral Oncogene Homolog [101]
rin beta-3 [102]
mobility group AT-hook 2 [103]
eukin 6 [104]
a B kinase [105]
n rat sarcoma viral oncogene homolog [106]
c Avian Myelocytomatosis Viral Oncogene a Derived Homolog [107]
c Avian Myelocytomatosis Viral Oncogene Homolog [108]
c Avian Myelocytomatosis Viral Oncogene Homolog [34]
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C.K. Thammaiah, S. Jayaram / Non-coding RNA Research xxx (2016) 1e64differentiation, self-renewal and therapy resistance [89,90]. Let-7 is
emerged as a master regulator of CSC properties including self-
renewal and tumor-seeding ability [91]. CSCs demonstrated
CD44þ/CD24/low antigen phenotype in mammosphere culture
conditions and treatment with anti-cancer reagents and have sig-
niﬁcant down-regulation of let-7 expression in BC cells. Further, let-
7 is shown to inhibit the self-renewal and de-differentiation ca-
pacity of BC cells by targeting several genes such as RAS and high
mobility group AT-hook 2 (HMGA2) [92]. Further, in BC let-7 is
found to suppress tumorigenicity and self-renewal capability by
targeting H-RAS and HMGA2 [92]. Delivery of miRNAs in lung
cancer using nucleic acid aptamers speciﬁc to the receptor tyrosine
kinase oncogene Axl, conjugated with let-7g, which target HMGA2,
showed effective inhibition of tumor growth [93,94]. Thus,
combining let-7with speciﬁc antibodies or aptamers against breast
CSCs, might be a useful approach to improve the treatment of BC
patients [95,96]. Considerable efforts have been made to improve
the target speciﬁc delivery of miRNA, however, more research is
required to improve the therapeutic efﬁcacy and design of vehicles
and methods for their delivery in vivo.
3. Conclusion
The research on miRNA have delivered several new aspects of
therapeutics and crossed a long way since its discovery. Multiple
parameters such as their small size and conserved sequence make
them a potential candidate for drug development program. Further,
miRNA targeted downstream genes that function in numerous
ways including growth, aggressiveness, and therapy resistance,
thus targeting single miRNA can have multiple implications. As let-
7 have shown multiple connections with metastasis and stemness
of BC, the day is not far off when let-7 will be a good therapeutic
target for the patients suffering from BC and other malignancies. In
addition altered expression of let-7 family members have been
shown to inﬂuence several other malignancies (Table 1). However,
the understanding of precise mechanism is required to gain more
insights into the therapeutic efﬁcacy of miRNAs.
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